Zineb Hamilou - Publications

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: December 15, 2025

A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with Pembrolizumab.

Journal: Current oncology (Toronto, Ont.)

Published: October 28, 2025

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: August 06, 2025

Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.

Journal: The oncologist

Published: May 23, 2025

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Journal: European urology oncology

Published: May 16, 2025

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 31, 2024

Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

Published: September 20, 2023

Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.

Journal: Oral oncology

Published: June 24, 2023

A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: January 31, 2022

Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: November 23, 2021

A drug safety evaluation of enzalutamide to treat advanced prostate cancer.

Journal: Expert opinion on drug safety

Published: June 11, 2021

Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

Journal: Therapeutic advances in medical oncology

Published: March 17, 2021